Background: The association between body mass index (BMI) and long-term outcomes of patients with ICC has not been well defined. We sought to define the presentation and oncologic outcomes of patients with ICC undergoing curative-intent resection, according to their BMI category. Methods: Patients who underwent resection of ICC were identified in a multi-institutional database. Patients were categorized as normal weight (BMI 18.5e24.9 kg/m2 ), overweight (BMI 25.0e29.9 kg/m2 ) and obese (BMI30 kg/m2 ) according to the World Health Organization (WHO) definition. Impact of clinico-pathological factors on recurrence-free survival (RFS) was assessed using Cox proportional hazards model among patients in the three BMI categories. Results: Among a total of 790 patients undergoing curative-intent resection of ICC in the analytic cohort, 399 (50.5%) had normal weight, 274 (34.7%) were overweight and 117 (14.8%) were obese. Caucasian patients were more likely to be obese (66.7%, n ¼ 78) and overweight (47.1%, n ¼ 129) compared with Asian (obese: 18.8%, n ¼ 22; overweight: 46%, n ¼ 126) and other races (obese: 14.5%, n ¼ 17; overweight: 6.9%, n ¼ 19)(p < 0.001). There were no differences in the presence of cirrhosis (10.9%, vs. 12.8%, vs. 12.9%), preoperative jaundice (8.6% vs. 9.5% vs. 12.0%), or levels of CA 19e9 (75, IQR 24.6e280 vs. 50.9, IQR 17.9 e232 vs. 43, IQR 16.9e192.7) among the BMI groups (all p > 0.05). On multivariable analysis, increased BMI was an independent risk factor for tumor recurrence (OR 1.16, 95% CI 1.02e1.32, for every 5 unit increase).

Additional Metadata
Keywords Intrahepatic cholangiocarcinoma, Recurrence, BMI, Obesity, Prognosis
Persistent URL,
Journal European Journal of Surgical Oncology
Merath, K., Mehta, R., Hyer, J.M., Bagante, F, Sahara, K., Alexandrescu, S., … Pawlik, TM. (2019). Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. European Journal of Surgical Oncology, 45(6), 1084–1091. doi:10.1016/j.ejso.2019.03.004